Patents by Inventor Hideaki Miyake
Hideaki Miyake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8536149Abstract: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN.Type: GrantFiled: May 4, 2012Date of Patent: September 17, 2013Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson
-
Publication number: 20130143944Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.Type: ApplicationFiled: January 9, 2013Publication date: June 6, 2013Applicant: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
-
Patent number: 8361981Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.Type: GrantFiled: April 29, 2009Date of Patent: January 29, 2013Assignee: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
-
Publication number: 20120322850Abstract: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN.Type: ApplicationFiled: May 4, 2012Publication date: December 20, 2012Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Helson
-
Patent number: 8173615Abstract: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer.Type: GrantFiled: April 5, 2010Date of Patent: May 8, 2012Assignee: Teva Pharmaceuticals Industries, Ltd.Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson
-
Publication number: 20120055909Abstract: Provided is a method of laser-welding that can achieve uniform welding of a member with large laser reflectance on a surface thereof A laser welding step (S1) includes a surface roughening step (S11) in which a first laser processing device irradiates laser light to a surface (each welding portion (31)) of a welding section (30, 30, 30, 30) between a negative electrode terminal (20) (a first member) and a negative electrode lead (21) (a second member) and carries out roughening, thereby forming a laser marker (32) on the surface; and a welding step (S12) in which a second laser processing device irradiates laser light to each welding portion (31) roughened in the surface roughening step (S11) and melts each welding portion (31), thereby carrying out the laser-welding of the negative electrode terminal (20) to the negative electrode lead (21).Type: ApplicationFiled: May 15, 2009Publication date: March 8, 2012Inventors: Hideaki Miyake, Takahiro Oshima
-
Patent number: 7896278Abstract: A wiring apparatus includes a spool; an annular reel surrounding the spool to be rotatable about an axis common with the spool, the reel being previously wound with a wire in layers to be wound on the spool; a winding arm for guiding the wire from the reel to the spool and placed outside the reel so as to be movable around the spool about the axis; a first motor and others for driving the winding arm and others to move around the spool to wind the wire on the spool; and a second motor and others for driving the reel to rotate on the axis to unreel the wire of a required length from the reel during driving of the first motor.Type: GrantFiled: October 10, 2007Date of Patent: March 1, 2011Assignee: Toyota Jidosha Kabushiki KaishaInventors: Hideaki Miyake, Shingo Hashimoto
-
Publication number: 20110021603Abstract: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer.Type: ApplicationFiled: April 5, 2010Publication date: January 27, 2011Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: MARTIN GLEAVE, PAUL S. RENNIE, HIDEAKI MIYAKE, COLLEEN NELSON
-
Publication number: 20100295412Abstract: A stator coil heating apparatus and a stator coil heating method that are capable of effectively preventing a core from thermal deformation particularly caused due to a magnetic flux generated by a coil head, without the problem of heating temperature variation, and also shortening a time for the process of heating a stator coil, are provided. A stator coil heating apparatus A to heat a stator coil L wound around a circular core F, comprises: induction heating coil heads 1 and 11 that heat the circular coil L by generating an inductive effect acting from outside in the thickness direction of the core F, against circular winding coil bases La and Lb that are sticking out of end faces Fa and Fb of the core F in the thickness direction thereof; and shields 2 and 12 that block a magnetic flux generated by the coil heads 1 and 11, out of the end faces Fa and Fb of the core F in the thickness direction thereof.Type: ApplicationFiled: January 11, 2008Publication date: November 25, 2010Applicants: KABUSHIKI KAISHA OET, TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Keishi Matsumoto, Kenichiro Fukumaru, Ikuo Hayashi, Hideaki Miyake, Hideaki Kimura, Satoshi Koide
-
Patent number: 7732422Abstract: Antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. Seq ID No. 4 (cagcagcagagtcttcatcat) is an antisense oligonucleotide which inhibits expression of TRPM-2 by tumor cells, and which can be combined with a pharmaceutically acceptable carrier suitable for human administration.Type: GrantFiled: October 19, 2007Date of Patent: June 8, 2010Assignee: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson
-
Publication number: 20090258089Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.Type: ApplicationFiled: April 29, 2009Publication date: October 15, 2009Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
-
Patent number: 7592323Abstract: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer.Type: GrantFiled: March 6, 2006Date of Patent: September 22, 2009Assignee: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson
-
Patent number: 7534773Abstract: Antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer for example prostate cancer and renal cell cancer. Antisense TRPM-2 ODN treatment of prostatic tumor cells in vivo is effective for delaying the onset of androgen independence and can be used in combination with androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed.Type: GrantFiled: February 25, 2000Date of Patent: May 19, 2009Assignee: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson
-
Patent number: 7491816Abstract: A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No.Type: GrantFiled: September 4, 2007Date of Patent: February 17, 2009Assignee: The University of British ColumbiaInventors: Gleave Martin, Hideaki Miyake
-
Publication number: 20090001211Abstract: A wiring apparatus includes a spool; an annular reel surrounding the spool to be rotatable about an axis common with the spool, the reel being previously wound with a wire in layers to be wound on the spool; a winding arm for guiding the wire from the reel to the spool and placed outside the reel so as to be movable around the spool about the axis; a first motor and others for driving the winding arm and others to move around the spool to wind the wire on the spool; and a second motor and others for driving the reel to rotate on the axis to unreel the wire of a required length from the reel during driving of the first motor.Type: ApplicationFiled: October 10, 2007Publication date: January 1, 2009Inventors: Hideaki Miyake, Shingo Hashimoto
-
Patent number: 7368436Abstract: It has been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer, particularly prostate and renal cell cancers. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence, thus prostate cancer can be treated by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in an individual, and administering a composition effective to inhibit expression of TRPM-2 by the tumor cells. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer and in human Renal cell cancer. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN.Type: GrantFiled: August 30, 2001Date of Patent: May 6, 2008Assignee: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson
-
Publication number: 20080064651Abstract: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer.Type: ApplicationFiled: October 19, 2007Publication date: March 13, 2008Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Martin Gleave, Paul Rennie, Hideaki Miyake, Colleen Nelson
-
Publication number: 20080051362Abstract: A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No.Type: ApplicationFiled: September 4, 2007Publication date: February 28, 2008Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Martin Gleave, Hideaki Miyake
-
Patent number: 7297684Abstract: A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No.Type: GrantFiled: July 19, 2000Date of Patent: November 20, 2007Assignee: The University of British ColumbiaInventors: Martin Gleave, Hideaki Miyake
-
Patent number: 6900187Abstract: A compound consisting of an oligonucleotide of sequence CAGCAGCAGAGTCTTCATCAT, where the oligonucleotide has a phosphorothioate backbone throughout, the sugar moieties of nucleotides 1-4 and 18-21 bear 2?-O-methoxyethyl modifications, and the remaining nucleotides (nucleotides 5-17) are 2?-deoxynucleotides, and where the cytosines of nucleotides 1, 4 and 19 are 5-methylcytosines. The compound has increased stability in vivo and improved in vitro and in vivo antitumor activity.Type: GrantFiled: February 22, 2002Date of Patent: May 31, 2005Assignee: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Brett P. Monia